Progesterone receptor antagonists

Details Progesterone receptor antagonists Progesterone receptor antagonists

2011-05-31

2011-05-31

Badio, Barbara P (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C552S648000

Reexamination Certificate

active

07951790

ABSTRACT:
The present invention relates to progesterone receptor antagonists of general formula I:in which R1 can be a hydrogen atom and R2 a hydroxyl group or R1 and R2 together can be an oxo group.

REFERENCES:
patent: 6225298 (2001-05-01), Spicer et al.
patent: 6316432 (2001-11-01), Schwede et al.
patent: 6825182 (2004-11-01), Ring et al.
patent: 2001/0016578 (2001-08-01), Spicer et al.
patent: 2280041 (1998-08-01), None
patent: WO 98/05679 (1992-02-01), None
patent: WO 98/05679 (1998-02-01), None
patent: WO-98 034947 (1998-08-01), None
patent: WO 02/32429 (2002-04-01), None
patent: WO-03 093292 (2003-11-01), None
Fuhrmann U et al, “Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist”, Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 43, No. 26, 2000, pp. 5010-5016, XP001064233.
Bagaria, M., et al., “Low-dose mifepristone in treatment of uterine leiomyoma: A randomized double-blind placebo-controlled clinical trial,” Australian and New Zealand Journal of Obstetrics and Gynaecology 2009; 49: 77-83.
Chwalisz, K., M.D., Ph.D., et al., “A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata,” Fertility and Sterility, vol. 87, No. 6, Jun. 2007, 1399-1412.
Furhmann, U., et al., “Synthesis and Biological Activity of a Novel, Highly Potent Progesterone Receptor Antagonist,” J. Med. Chem. 2000, 43, 5010-5016.
Kettel, L.M., M.D., et al., “Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486),” Am. J. Obstet. Gynecol. 1998; 178: 1151-1156.
Kettel, L.M., M.D et al., “Treatment of endometriosis with the antiprogesterone mifepristone (RU 486)†‡,” Fertility and Sterility, vol. 65, No. 1, Jan. 1996, 23-28.
Kettel, L.M., M.D., et al., “Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis †,” Fertility and Sterility, vol. 56, No. 3, Sep. 1991, 402-407.
Moller, C., et al., “Investigational developments for the treatment of progesterone-dependent diseases,” Expert Opin. Investig. Drugs (2008) 17(4): 469-479.
Murphy, A.A., et al., “Regression of uterine leiomyomata in response to the antiprogesterone RU 486,” The J. Clin. Endocrinol. Metab, 1993 76: 513-517.
Steinauer, J., M.D., et al., “Systematic Review of Mifepristone for the Treatment of Uterine Leiomyomata,” American College of Obeste. and Gynecol., vol. 103, No. 6, Jun. 2004, 1331-1336.

Affiliated with

Also associated with

Rating

Progesterone receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Progesterone receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Progesterone receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2620140